YONG LI to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications YONG LI has written about Xenograft Model Antitumor Assays.
Connection Strength
0.225
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
Score: 0.148
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
Score: 0.045
-
CircARHGAP12 promotes nasopharyngeal carcinoma migration and invasion via ezrin-mediated cytoskeletal remodeling. Cancer Lett. 2021 01 01; 496:41-56.
Score: 0.033